Gilead Sciences Inc.

13 de ago. de 2026, 23:11 UTC

Gilead Sciences shares are lower in after-market trading, reflecting routine activity amid broader economic data showing rising jobless claims and steady producer prices.

12 de ago. de 2026, 20:06 UTC

Gilead Sciences announced a collaboration with Nucleai for AI-driven biomarker discovery. Shares are trading lower despite the partnership announcement.

11 de ago. de 2026, 20:06 UTC

Gilead Sciences reported second-quarter revenue of $7.80 billion, exceeding estimates. Shares are higher since Monday, reflecting positive sentiment after the earnings report.

10 de ago. de 2026, 23:06 UTC

Gilead Sciences Inc. shares are higher in after-market hours, reflecting stability with routine trading and no specific news identified.

7 de ago. de 2026, 20:06 UTC

Gilead Sciences reports $65 million in revenue from Kymera Therapeutics collaboration, including a $45 million option exercise fee. Shares are higher despite earlier session pullback.

6 de ago. de 2026, 23:02 UTC

Gilead Sciences filed a mixed securities shelf, raising investor concerns about share dilution. Shares are trading lower in after-market hours.

5 de ago. de 2026, 19:53 UTC

Gilead Sciences shares are lower after reporting a $10.50 billion net loss and revising fiscal 2026 earnings guidance downward, despite strong HIV sales.

4 de ago. de 2026, 23:02 UTC

Gilead Sciences reports a $10.50 billion net loss for Q2, lowering full-year GAAP EPS guidance. Shares are trading lower in after-market hours.

3 de ago. de 2026, 19:51 UTC

Gilead Sciences advances following a California Supreme Court ruling on HIV drug innovation, boosting investor sentiment ahead of Q2 earnings report.

31 de jul. de 2026, 23:16 UTC

Gilead Sciences shares are higher in after-market trading amid market fluctuations. Accessibility challenges for lenacapavir in Latin America may impact potential sales.

30 de jul. de 2026, 21:31 UTC

Gilead Sciences shares are lower in after-market hours, continuing a decline since Thursday's close and remaining below the 20-day moving average.

29 de jul. de 2026, 22:41 UTC

Gilead Sciences Inc shares are lower in after-market trading, with no specific news identified to explain the decline amid notable volatility earlier in the session.

28 de jul. de 2026, 23:01 UTC

Gilead Sciences received endorsement for Trodelvy with Keytruda for specific breast cancer patients, boosting shares modestly higher in after-market trading.

27 de jul. de 2026, 18:07 UTC

Morgan Stanley maintains Overweight rating on Gilead Sciences, lowering price target to $165. Shares are higher since Friday, supported by positive news on Trodelvy.

24 de jul. de 2026, 21:41 UTC

Gilead Sciences receives positive CHMP opinion for Trodelvy and Keytruda combination, with shares rising in after-market trading despite broader market volatility.

22 de jul. de 2026, 19:11 UTC

Gilead Sciences Inc is gaining Wednesday, having pulled back earlier in the session. Broader market sentiment is influenced by rising crude oil prices and geopolitical tensions.

21 de jul. de 2026, 19:41 UTC

Gilead Sciences shares are lower after Leerink Partners downgraded the stock to Market Perform and cut the price target to $127 from $146.

20 de jul. de 2026, 23:01 UTC

Gilead Sciences shares are lower in after-market hours following a downgrade from Leerink Partners, citing challenges in the HIV prophylaxis market and revised sales outlook.

17 de jul. de 2026, 19:56 UTC

Gilead Sciences shares are lower as the company missed full-year EPS estimates despite reporting $6.96 billion in revenue, reflecting heightened market volatility.

16 de jul. de 2026, 23:41 UTC

Gilead Sciences Inc. shares moved higher in after-market trading, remaining above their 20-day moving average following three consecutive daily gains.

15 de jul. de 2026, 18:46 UTC

Gilead Sciences Inc shares are higher, reflecting positive momentum in biotechnology amid a declining U.S. Dollar and easing inflation concerns.

14 de jul. de 2026, 23:16 UTC

Gilead Sciences shares are higher in after-market trading, following a steady increase from earlier lows amid softer inflation data and a rally in Treasury bonds.

13 de jul. de 2026, 17:26 UTC

Gilead Sciences is gaining as it prepares for key product launches in 2026, including Bulevirtide and a new HIV regimen under FDA review.

10 de jul. de 2026, 20:01 UTC

Gilead Sciences is highlighted as a resilient dividend stock, yet shares are trading lower amid broader market volatility and recent declines.

9 de jul. de 2026, 19:36 UTC

Gilead Sciences Inc's shares are lower despite regulatory achievements for Trodelvy and advancements in its HIV pipeline, reflecting broader market volatility.

8 de jul. de 2026, 23:51 UTC

Gilead Sciences shares are lower in after-hours trading, reflecting a decline from earlier levels amid broader market weakness influenced by geopolitical tensions.

7 de jul. de 2026, 23:02 UTC

Gilead Sciences Inc. shares are lower in after-market hours, reflecting broader market declines amid rising geopolitical tensions and a widening U.S. trade deficit.

6 de jul. de 2026, 20:02 UTC

Gilead Sciences is trading lower amid a Biotechnology sector decline, despite HSBC's upgrade to Buy and a raised price target of $155.

2 de jul. de 2026, 22:56 UTC

Gilead Sciences shares traded lower in after-market hours, with no specific news identified. Broader market mixed amid weaker U.S. jobless data.

1 de jul. de 2026, 19:14 UTC

Gilead Sciences Inc. shares are lower today, reflecting routine performance within their one-month trading range despite stability around the midpoint.